Literature DB >> 1622182

Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in rats.

M G Wientjes1, J L Au.   

Abstract

We investigated the pharmacokinetic interaction between 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxyinosine (ddI), given to rats by intravenous injection. For both compounds, the clearances, terminal half-lives, and fractions of the dose excreted unchanged in urine were not altered by the other drug (P greater than 0.05), indicating no pharmacokinetic interaction between the two drugs.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1622182      PMCID： PMC190576          DOI： 10.1128/AAC.36.3.665

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Initial clinical experience with dideoxynucleosides as single agents and in combination therapy.

Authors:  R Yarchoan; J M Pluda; C F Perno; H Mitsuya; R V Thomas; K M Wyvill; S Broder
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

2.  Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity.

Authors:  D A Cooney; G Ahluwalia; H Mitsuya; A Fridland; M Johnson; Z Hao; M Dalal; J Balzarini; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1987-06-01       Impact factor: 5.858

3.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

4.  Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleoside substrates.

Authors:  J D Stoeckler; C Cambor; R E Parks
Journal:  Biochemistry       Date:  1980-01-08       Impact factor: 3.162

5.  Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells.

Authors:  M A Johnson; A Fridland
Journal:  Mol Pharmacol       Date:  1989-08       Impact factor: 4.436

6.  Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.

Authors:  R W Klecker; J M Collins; R Yarchoan; R Thomas; J F Jenkins; S Broder; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

Review 7.  Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report.

Authors:  R Yarchoan; S Broder
Journal:  N Engl J Med       Date:  1987-02-26       Impact factor: 91.245

8.  Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats.

Authors:  B A Patel; C K Chu; F D Boudinot
Journal:  J Pharm Sci       Date:  1989-07       Impact factor: 3.534

9.  The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles.

Authors:  R Yarchoan; H Mitsuya; J M Pluda; K S Marczyk; R V Thomas; N R Hartman; P Brouwers; C F Perno; J P Allain; D G Johns
Journal:  Rev Infect Dis       Date:  1990 Jul-Aug

10.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205
View more
  5 in total

1.  Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina.

Authors:  T Tuntland; R J Ravasco; S al-Habet; J D Unadkat
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

2.  Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.

Authors:  M Barry; J L Howe; S Ormesher; D J Back; A M Breckenridge; C Bergin; F Mulcahy; N Beeching; F Nye
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

3.  Renal disposition and drug interaction screening of (-)-2'-deoxy-3'-thiacytidine (3TC) in the isolated perfused rat kidney.

Authors:  K R Sweeney; P H Hsyu; P Statkevich; D R Taft
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

4.  Effect of zidovudine on transplacental pharmacokinetics of ddI in the pigtailed macaque (Macaca nemestrina).

Authors:  C M Pereira; C Nosbisch; W L Baughman; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

5.  Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.

Authors:  D Gibb; M Barry; S Ormesher; L Nokes; M Seefried; C Giaquinto; D Back
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.